<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 20:07:38 -0700</creation_date>
  <update_date>2013-01-15 20:07:38 -0700</update_date>
  <accession>HMDBP08203</accession>
  <secondary_accessions>
    <accession>13914</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>GABA(A) receptor subunit alpha-6</synonym>
  </synonyms>
  <gene_name>GABRA6</gene_name>
  <general_function>Involved in ion transport</general_function>
  <specific_function>GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00492</accession>
      <name>Chlorine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00112</accession>
      <name>Gamma-Aminobutyric acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14332</accession>
      <name>Lorazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14335</accession>
      <name>Ethchlorvynol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14376</accession>
      <name>Temazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14382</accession>
      <name>Butabarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14386</accession>
      <name>Butalbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14451</accession>
      <name>Talbutal</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14457</accession>
      <name>Pentobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14493</accession>
      <name>Clobazam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14515</accession>
      <name>Meprobamate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13943</accession>
      <name>Alpha-hydroxyalprazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14562</accession>
      <name>Secobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14606</accession>
      <name>Metharbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14618</accession>
      <name>Chlordiazepoxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14737</accession>
      <name>Thiopental</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14766</accession>
      <name>Clorazepate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14821</accession>
      <name>Midazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14828</accession>
      <name>Flurazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14932</accession>
      <name>Primidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14980</accession>
      <name>Oxazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14987</accession>
      <name>Methylphenobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15034</accession>
      <name>Triazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15440</accession>
      <name>Amobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15441</accession>
      <name>Aprobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15442</accession>
      <name>Butethal</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15443</accession>
      <name>Heptabarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13940</accession>
      <name>3'-Hydroxyhexobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15510</accession>
      <name>Flunitrazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15511</accession>
      <name>Bromazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15534</accession>
      <name>Nitrazepam</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>ligand-gated ion channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>extracellular ligand-gated ion channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>substrate-specific transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>molecular transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>signal transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>gaba receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>gaba-a receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cell surface receptor linked signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>g-protein coupled receptor protein signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>gamma-aminobutyric acid signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>anion transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>inorganic anion transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>chloride transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>establishment of localization</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>ion transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>postsynaptic membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cell junction</subcellular_location>
    <subcellular_location>synapse</subcellular_location>
    <subcellular_location>postsynaptic cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
    <subcellular_location>Cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:5</chromosome_location>
    <locus>5q34</locus>
    <gene_sequence>&gt;1362 bp
ATGGCGTCGTCTCTGCCCTGGCTGTGCATTATTCTGTGGCTAGAAAATGCCCTAGGGAAA
CTCGAAGTTGAAGGCAACTTCTACTCAGAAAACGTCAGTCGGATCCTGGACAACTTGCTT
GAAGGCTATGACAATCGGCTGCGGCCGGGATTTGGAGGTGCTGTCACTGAAGTCAAAACA
GACATTTATGTGACCAGTTTTGGGCCCGTGTCAGATGTGGAGATGGAGTATACGATGGAT
GTTTTTTTCCGCCAGACCTGGACTGATGAGAGGTTGAAGTTTGGGGGGCCAACTGAGATT
CTGAGTCTGAATAATTTGATGGTCAGTAAAATCTGGACGCCTGACACCTTTTTCAGAAAT
GGTAAAAAGTCCATTGCTCACAACATGACAACTCCTAATAAACTCTTCAGAATAATGCAG
AATGGAACCATTTTATACACCATGAGGCTTACCATCAATGCTGACTGTCCCATGAGGCTG
GTTAACTTTCCTATGGATGGGCATGCTTGTCCACTCAAGTTTGGGAGCTATGCTTATCCC
AAAAGTGAAATCATATATACGTGGAAAAAAGGACCACTTTACTCAGTAGAAGTCCCAGAA
GAATCTTCAAGCCTTCTCCAGTATGACCTGATTGGACAAACAGTATCTAGTGAGACAATT
AAATCTAACACAGGTGAATACGTTATAATGACAGTTTACTTCCACTTGCAAAGGAAGATG
GGCTACTTCATGATACAGATATACACTCCTTGCATTATGACAGTCATTCTTTCCCAGGTG
TCTTTCTGGATTAATAAGGAGTCCGTCCCAGCAAGAACTGTTTTTGGGATCACCACTGTT
TTAACTATGACCACTTTGAGCATCAGTGCCCGGCACTCTTTGCCAAAAGTGTCATATGCC
ACTGCCATGGATTGGTTCATAGCTGTTTGCTTTGCATTCGTCTTCTCTGCTCTTATCGAG
TTCGCAGCTGTCAACTACTTTACCAATCTTCAGACACAGAAGGCCAAAAGGAAGGCACAG
TTTGCAGCCCCACCCACAGTGACAATATCAAAAGCTACTGAACCTTTGGAAGCTGAGATT
GTTTTGCATCCTGACTCCAAATATCATCTGAAGAAAAGGATCACTTCTCTGTCTTTGCCA
ATAGTTTCATCTTCCGAGGCCAATAAAGTGCTCACGAGAGCGCCCATCTTACAATCAACA
CCTGTCACACCCCCACCACTCTCGCCAGCCTTTGGAGGCACCAGTAAAATAGACCAGTAT
TCTCGAATTCTCTTCCCAGTTGCATTTGCAGGATTCAACCTTGTGTACTGGGTAGTTTAT
CTTTCCAAAGATACAATGGAAGTGAGTAGCAGTGTTGAATAG</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>453</residue_number>
    <molecular_weight>51023.7</molecular_weight>
    <theoretical_pi>8.4</theoretical_pi>
    <pfams>
      <pfam>
        <name>Neur_chan_LBD</name>
        <pfam_id>PF02931</pfam_id>
      </pfam>
      <pfam>
        <name>Neur_chan_memb</name>
        <pfam_id>PF02932</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>243-264</region>
      <region>269-290</region>
      <region>301-324</region>
      <region>420-441</region>
    </transmembrane_regions>
    <signal_regions>
      <region>1-19</region>
    </signal_regions>
    <protein_sequence>&gt;Gamma-aminobutyric acid receptor subunit alpha-6
MASSLPWLCIILWLENALGKLEVEGNFYSENVSRILDNLLEGYDNRLRPGFGGAVTEVKT
DIYVTSFGPVSDVEMEYTMDVFFRQTWTDERLKFGGPTEILSLNNLMVSKIWTPDTFFRN
GKKSIAHNMTTPNKLFRIMQNGTILYTMRLTINADCPMRLVNFPMDGHACPLKFGSYAYP
KSEIIYTWKKGPLYSVEVPEESSSLLQYDLIGQTVSSETIKSNTGEYVIMTVYFHLQRKM
GYFMIQIYTPCIMTVILSQVSFWINKESVPARTVFGITTVLTMTTLSISARHSLPKVSYA
TAMDWFIAVCFAFVFSALIEFAAVNYFTNLQTQKAKRKAQFAAPPTVTISKATEPLEAEI
VLHPDSKYHLKKRITSLSLPIVSSSEANKVLTRAPILQSTPVTPPPLSPAFGGTSKIDQY
SRILFPVAFAGFNLVYWVVYLSKDTMEVSSSVE</protein_sequence>
  </protein_properties>
  <genbank_protein_id>158259945</genbank_protein_id>
  <uniprot_id>Q16445</uniprot_id>
  <uniprot_name>GBRA6_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>AK289461</genbank_gene_id>
  <genecard_id>GABRA6</genecard_id>
  <geneatlas_id>GABRA6</geneatlas_id>
  <hgnc_id>HGNC:4080</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Hadingham KL, Garrett EM, Wafford KA, Bain C, Heavens RP, Sirinathsinghji DJ, Whiting PJ: Cloning of cDNAs encoding the human gamma-aminobutyric acid type A receptor alpha 6 subunit and characterization of the pharmacology of alpha 6-containing receptors. Mol Pharmacol. 1996 Feb;49(2):253-9.</reference_text>
      <pubmed_id>8632757</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers.  Science. 2006 Oct 13;314(5797):268-74. Epub 2006 Sep 7.</reference_text>
      <pubmed_id>16959974</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Lorazepam</name>
        <accession>HMDB14332</accession>
      </metabolite>
      <reference>
        <reference_text>Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4.</reference_text>
        <pubmed_id>20138190</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lorazepam</name>
        <accession>HMDB14332</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lorazepam</name>
        <accession>HMDB14332</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethchlorvynol</name>
        <accession>HMDB14335</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethchlorvynol</name>
        <accession>HMDB14335</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Temazepam</name>
        <accession>HMDB14376</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Temazepam</name>
        <accession>HMDB14376</accession>
      </metabolite>
      <reference>
        <reference_text>Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4.</reference_text>
        <pubmed_id>20138190</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butabarbital</name>
        <accession>HMDB14382</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butabarbital</name>
        <accession>HMDB14382</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butalbital</name>
        <accession>HMDB14386</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butalbital</name>
        <accession>HMDB14386</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Talbutal</name>
        <accession>HMDB14451</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Talbutal</name>
        <accession>HMDB14451</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pentobarbital</name>
        <accession>HMDB14457</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pentobarbital</name>
        <accession>HMDB14457</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clobazam</name>
        <accession>HMDB14493</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clobazam</name>
        <accession>HMDB14493</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meprobamate</name>
        <accession>HMDB14515</accession>
      </metabolite>
      <reference>
        <reference_text>Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91.</reference_text>
        <pubmed_id>9067327</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meprobamate</name>
        <accession>HMDB14515</accession>
      </metabolite>
      <reference>
        <reference_text>Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. Epub 2009 Feb 24.</reference_text>
        <pubmed_id>19244096</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alpha-hydroxyalprazolam</name>
        <accession>HMDB13943</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Secobarbital</name>
        <accession>HMDB14562</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Secobarbital</name>
        <accession>HMDB14562</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Metharbital</name>
        <accession>HMDB14606</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Metharbital</name>
        <accession>HMDB14606</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlordiazepoxide</name>
        <accession>HMDB14618</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlordiazepoxide</name>
        <accession>HMDB14618</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Thiopental</name>
        <accession>HMDB14737</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Thiopental</name>
        <accession>HMDB14737</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clorazepate</name>
        <accession>HMDB14766</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clorazepate</name>
        <accession>HMDB14766</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midazolam</name>
        <accession>HMDB14821</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midazolam</name>
        <accession>HMDB14821</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flurazepam</name>
        <accession>HMDB14828</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flurazepam</name>
        <accession>HMDB14828</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Primidone</name>
        <accession>HMDB14932</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Primidone</name>
        <accession>HMDB14932</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxazepam</name>
        <accession>HMDB14980</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxazepam</name>
        <accession>HMDB14980</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenobarbital</name>
        <accession>HMDB14987</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenobarbital</name>
        <accession>HMDB14987</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenobarbital</name>
        <accession>HMDB14987</accession>
      </metabolite>
      <reference>
        <reference_text>Olsen RW, Li GD: GABA(A) receptors as molecular targets of general anesthetics: identification of binding sites provides clues to allosteric modulation. Can J Anaesth. 2011 Feb;58(2):206-15. Epub 2010 Dec 31.</reference_text>
        <pubmed_id>21194017</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Triazolam</name>
        <accession>HMDB15034</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Triazolam</name>
        <accession>HMDB15034</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amobarbital</name>
        <accession>HMDB15440</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amobarbital</name>
        <accession>HMDB15440</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aprobarbital</name>
        <accession>HMDB15441</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aprobarbital</name>
        <accession>HMDB15441</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butethal</name>
        <accession>HMDB15442</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butethal</name>
        <accession>HMDB15442</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Heptabarbital</name>
        <accession>HMDB15443</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Heptabarbital</name>
        <accession>HMDB15443</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3'-Hydroxyhexobarbital</name>
        <accession>HMDB13940</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3'-Hydroxyhexobarbital</name>
        <accession>HMDB13940</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flunitrazepam</name>
        <accession>HMDB15510</accession>
      </metabolite>
      <reference>
        <reference_text>Santhakumar V, Hanchar HJ, Wallner M, Olsen RW, Otis TS: Contributions of the GABAA receptor alpha6 subunit to phasic and tonic inhibition revealed by a naturally occurring polymorphism in the alpha6 gene. J Neurosci. 2006 Mar 22;26(12):3357-64.</reference_text>
        <pubmed_id>16554486</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flunitrazepam</name>
        <accession>HMDB15510</accession>
      </metabolite>
      <reference>
        <reference_text>You H, Kozuska JL, Paulsen IM, Dunn SM: Benzodiazepine modulation of the rat GABAA receptor alpha4beta3gamma2L subtype expressed in Xenopus oocytes. Neuropharmacology. 2010 Nov;59(6):527-33. Epub 2010 Jul 16.</reference_text>
        <pubmed_id>20638393</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flunitrazepam</name>
        <accession>HMDB15510</accession>
      </metabolite>
      <reference>
        <reference_text>Skilbeck KJ, O'Reilly JN, Johnston GA, Hinton T: Antipsychotic drug administration differentially affects [3H]muscimol and [3H]flunitrazepam GABA(A) receptor binding sites. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):492-8. Epub 2007 Oct       10.</reference_text>
        <pubmed_id>17976880</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromazepam</name>
        <accession>HMDB15511</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nitrazepam</name>
        <accession>HMDB15534</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nitrazepam</name>
        <accession>HMDB15534</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
